YAP1 and breast cancer: More recently, breast cancer PDX models that preserve patient intratumoral heterogeneity and clonal architecture have been reported, including endocrine therapy-resistant models that feature ERα Y537 mutations, ESR1 gene amplification, or ESR1/YAP1 fusion [47, 74].